炎症性肠病合并胰腺疾病的诊治策略

郭晓钟

doi:10.3969/j.issn.1001-5256.2020.07.004

炎症性肠病合并胰腺疾病的诊治策略

DOI: 10.3969/j.issn.1001-5256.2020.07.004

郭晓钟

北部战区总医院消化内科

详细信息

中图分类号: R576;R574
计量
- 文章访问数: 1169
- HTML全文浏览量: 27
- PDF下载量: 342
- 被引次数: 0
出版历程
- 出版日期: 2020-07-20

Diagnosis and treatment strategies for pancreatic diseases in patients with inflammatory bowel disease

Guo XiaoZhong

Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang 110840, China

摘要

摘要:
炎症性肠病是一种多系统疾病,合并胰腺疾病需受到临床的关注。系统阐述了炎症性肠病合并急性胰腺炎、慢性胰腺炎、自身免疫性胰腺炎、胰腺外分泌功能不全、胰腺癌和无症状实验室检查及影像学异常的研究概况,并分析各种疾病的诊治策略,为临床发现、处置该类疾病提供重要参考。
- 炎症性肠病 /
- 胰腺疾病 /
- 诊断 /
- 治疗学
Abstract:
Inflammatory bowel disease( IBD) is a multisystem disease,and pancreatic diseases in patients with IBD should be taken seriously in clinical practice. This article systematically elaborates on the research status of acute pancreatitis,chronic pancreatitis,autoimmune pancreatitis,pancreatic exocrine dysfunction,pancreatic cancer,and asymptomatic laboratory examination and imaging abnormalities in IBD patients and analyzes the diagnosis and treatment strategies for these diseases,so as to provide an important reference for clinical identification and treatment of such diseases.
- inflammatory bowel disease /
- pancreatic diseases /
- diagnosis /
- therapeutics

HTML全文

参考文献(71)

[1]MOLODECKY NA,SOON IS,RABI DM,et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology,2012,142(1):46-54.e42;quiz e30．

[2]IIDA T,YOKOYAMA Y,WAGATSUMA K,et al.Impact of autophagy of innate immune cells on inflammatory bowel disease[J].Cells,2018,8(1):7．

[3]VAVRICKA SR,SCHOEPFER A,SCHARL M,et al.Extraintestinal manifestations of inflammatory bowel disease[J].Inflamm Bowel Dis,2015,21(8):1982-1992．

[4]PITCHUMONI CS,RUBIN A,DAS K.Pancreatitis in inflammatory bowel diseases[J].J Clin Gastroenterol,2010,44(4):246-253．

[5]HEIKIUS B,NIEMELS,LEHTOLA J,et al.Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease[J].Am J Gastroenterol,1999,94(4):1062-1069．

[6]CHEN YT,SU JS,TSENG CW,et al.Inflammatory bowel disease on the risk of acute pancreatitis:A population-based cohort study[J].J Gastroenterol Hepatol,2016,31(4):782-787．

[7]FOUSEKIS FS,KATSANOS KH,THEOPISTOS VI,et al.Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases:A referral center study[J].BMC Gastroenterol,2019,19(1):48．

[8]GIZARD E,FORD AC,BRONOWICKI JP,et al.Systematic review:The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther,2014,40(1):3-15．

[9]ZHANG FM,XU CF,SHAN GD,et al.Is gallstone disease associated with inflammatory bowel diseases?A meta-analysis[J].J Dig Dis,2015,16(11):634-641．

[10]JEONG YH,KIM KO,LEE HC,et al.Gallstone prevalence and risk factors in patients with ulcerative colitis in Korean population[J].Medicine(Baltimore),2017,96(31):e7653．

[11]CHEN CH,LIN CL,KAO CH.Association between inflammatory bowel disease and Cholelithiasis:A nationwide population-based cohort study[J].Int J Environ Res Public Health,2018,15(3):513．

[12]MAURER P,HAAG K,ROTH M,et al.No evidence for abnormal gallbladder emptying in Crohn's disease[J].Hepatogastroenterology,1996,43(10):807-812．

[13]PARENTE F,PASTORE L,BARGIGGIA S,et al.Incidence and risk factors for gallstones in patients with inflammatory bowel disease:A large case-control study[J].Hepatology,2007,45(5):1267-1274．

[14]TEICH N,MOHL W,BOKEMEYER B,et al.Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases-a prospective study on incidence and severity[J].J Crohns Colitis,2016,10(1):61-68．

[15]LEDDER O,LEMBERG DA,DAY AS.Thiopurine-induced pancreatitis in inflammatory bowel diseases[J].Expert Rev Gastroenterol Hepatol,2015,9(4):399-403．

[16]BERMEJO F,LOPEZ-SANROMAN A,TAXONERA C,et al.A-cute pancreatitis in inflammatory bowel disease,with special reference to azathioprine-induced pancreatitis[J].Aliment Pharmacol Ther,2008,28(5):623-628．

[17]WILSON A,JANSEN LE,ROSE RV,et al.HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease[J].Aliment Pharmacol Ther,2018,47(5):615-620．

[18]RIBALDONE DG,ADRIANI A,CAVIGLIA GP,et al.Correlation between thiopurine S-methyltransferase genotype and adverse events in inflammatory bowel disease patients[J].Medicina(Kaunas),2019,55(8):441．

[19]GARAU P,ORENSTEIN SR,NEIGUT DA,et al.Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis[J].J Pediatr Gastroenterol Nutr,1994,18(4):481-485．

[20]RANSFORD RA,LANGMAN MJ.Sulphasalazine and mesalazine:Serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines[J].Gut,2002,51(4):536-539．

[21]FERNNDEZ J,SALA M,PANS J,et al.Acute pancreatitis after long-term 5-aminosalicylic acid therapy[J].Am J Gastroenterol,1997,92(12):2302-2303．

[22]FAINTUCH J,MOTT CB,MACHADO MC.Pancreatitis and pancreatic necrosis during sulfasalazine therapy[J].Int Surg,1985,70(3):271-272．

[23]SRINATH AI,GUPTA N,HUSAIN SZ.Probing the association of pancreatitis in inflammatory bowel disease[J].Inflamm Bowel Dis,2016,22(2):465-475．

[24]MECZKER，MIKA,GEDE N,et al.Retrospective matched-cohort analysis of acute pancreatitis induced by 5-aminosalicylic acid-derived drugs[J].Pancreas,2019,48(4):488-495．

[25]WERLANG ME,LEWIS MD,BARTEL MJ.Tumor necrosis factor alpha inhibitor-induced acute pancreatitis[J].ACG Case Rep J,2017,4:e103．

[26]PICARDO S,SO K,VENUGOPAL K,et al.Vedolizumab-induced acute pancreatitis:The first reported clinical case[J].BMJ Case Rep,2018,2018:bcr2017222554．

[27]STOBAUGH DJ,DEEPAK P.Effect of tumor necrosis factor-αinhibitors on drug-induced pancreatitis in inflammatory bowel disease[J].Ann Pharmacother,2014,48(10):1282-1287．

[28] NITSCHE C,MAERTIN S,SCHEIBER J,et al.Drug-induced pancreatitis[J].Curr Gastroenterol Rep,2012,14(2):131-138．

[29]FORSMARK CE,BAILLIE J,AGA Institute Clinical Practice and Economics Committee,et al.AGA Institute technical review on acute pancreatitis[J].Gastroenterology,2007,132(5):2022-2044．

[30] SADR-AZODI O,MATTSSON F,BEXLIUS TS,et al.Association of oral glucocorticoid use with an increased risk of acute pancreatitis:A population-based nested case-control study[J].JAMA Intern Med,2013,173(6):444-449．

[31]LEGGE DA,HOFFMAN HN 2nd,CARLSON HC.Pancreatitis as a complication of regional enteritis of the duodenum[J].Gastroenterology,1971,61(6):834-837．

[32]GSCHWANTLER M,KOGELBAUER G,KLOSE W,et al.The pancreas as a site of granulomatous inflammation in Crohn's disease[J].Gastroenterology,1995,108(4):1246-1249．

[33]MELTZER SJ,KORELITZ BI.Pancreatitis and duodenopancreatic reflux in Crohn's disease.Case report and review of the literature[J].J Clin Gastroenterol,1988,10(5):555-558．

[34]FOUSEKIS FS,THEOPISTOS VI,KATSANOS KH,et al.Pancreatic involvement in inflammatory bowel disease:A review[J].J Clin Med Res,2018,10(10):743-751．

[35]GOLDIN E,LIBSON E,WENGROWER D,et al.Severe acute pancreatitis as the presenting symptom of primary sclerosing cholangitis:Treatment by endoscopic insertion of a biliary stent[J].Int Surg,1990,75(1):58-60．

[36]SAID K,GLAUMANN H,BERGQUIST A.Gallbladder disease in patients with primary sclerosing cholangitis[J].J Hepatol,2008,48(4):598-605．

[37]NITSCHE C,MAERTIN S,SCHEIBER J,et al.Drug-induced pancreatitis[J].Curr Gastroenterol Rep,2012,14(2):131-138．

[38]DONG LH,LIU ZM,WANG SJ,et al.Corticosteroid therapy for severe acute pancreatitis:A meta-analysis of randomized,controlled trials[J].Int J Clin Exp Pathol,2015,8(7):7654-7660．

[39]TRIANTAFILLIDIS JK,CHERACAKIS P,HERETI IA,et al.Acute idiopathic pancreatitis complicating active Crohn's disease:Favorable response to infliximab treatment[J].Am J Gastroenterol,2000,95(11):3334-3336．

[40]KHANDELWAL A,INOUE D,TAKAHASHI N.Autoimmune pancreatitis:An update[J].Abdom Radiol(NY),2020,45(5):1359-1370．

[41]IIDA T,WAGATSUMA K,HIRAYAMA D,et al.The etiology of pancreatic manifestations in patients with inflammatory bowel disease[J].J Clin Med,2019,8(7):916．

[42]TSEN A,ALISHAHI Y,ROSENKRANZ L.Autoimmune pancreatitis and inflammatory bowel disease:An updated review[J].J Clin Gastroenterol,2017,51(3):208-214．

[43]UEKI T,KAWAMOTO K,OTSUKA Y,et al.Prevalence and clinicopathological features of autoimmune pancreatitis in Japanese patients with inflammatory bowel disease[J].Pancreas,2015,44(3):434-440．

[44]LORENZO D,MAIRE F,STEFANESCU C,et al.Features of autoimmune pancreatitis associated with inflammatory bowel diseases[J].Clin Gastroenterol Hepatol,2018,16(1):59-67．

[45]RAVI K,CHARI ST,VEGE SS,et al.Inflammatory bowel disease in the setting of autoimmune pancreatitis[J].Inflamm Bowel Dis,2009,15(9):1326-1330．

[46]SHIMOSEGAWA T,CHARI ST,FRULLONI L,et al.International consensus diagnostic criteria for autoimmune pancreatitis:Guidelines of the International Association of Pancreatology[J].Pancreas,2011,40(3):352-358．

[47]CONWELL DL,LEE LS,YADAV D,et al.American pancreatic association practice guidelines in chronic pancreatitis:Evidence-based report on diagnostic guidelines[J].Pancreas,2014,43(8):1143-1162．

[48]BARTHET M,HASTIER P,BERNARD JP,et al.Chronic pancreatitis and inflammatory bowel disease:True or coincidental association?[J].Am J Gastroenterol,1999,94(8):2141-2148．

[49]CHEN YL,HSU CW,CHENG CC,et al.Increased subsequent risk of inflammatory bowel disease association in patients with chronic pancreatitis:A nationwide population-based cohort study[J].Curr Med Res Opin,2017,33(6):1077-1082．

[50]ZAMBONI GA,AMBROSETTI MC,PEZZULLO M,et al.Optimum imaging of chronic pancreatitis[J].Abdom Radiol(NY),2020,45(5):1410-1419．

[51]SINGH VK,YADAV D,GARG PK.Diagnosis and management of chronic pancreatitis:A review[J].JAMA,2019,322(24):2422-2434．

[52]SHARZEHI K.Management of pancreatic duct stones[J].Curr Gastroenterol Rep,2019,21(11):63．

[53]CAPURSO G,TRAINI M,PICIUCCHI M,et al.Exocrine pancreatic insufficiency:Prevalence,diagnosis,and management[J].Clin Exp Gastroenterol,2019,12:129-139．

[54]MACONI G,DOMINICI R,MOLTENI M,et al.Prevalence of pancreatic insufficiency in inflammatory bowel diseases.Assessment by fecal elastase-1[J].Dig Dis Sci,2008,53(1):262-270．

[55]ANGELINI G,CAVALLINI G,BOVO P,et al.Pancreatic function in chronic inflammatory bowel disease[J].Int J Pancreatol,1988,3(2-3):185-193．

[56]HEIKIUS B,NIEMELS,LEHTOLA J,et al.Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease[J].Scand J Gastroenterol,1996,31(5):517-523．

[57]SINGH VK,HAUPT ME,GELLER DE,et al.Less common etiologies of exocrine pancreatic insufficiency[J].World J Gastroenterol,2017,23(39):7059-7076．

[58]de la IGLESIA-GARCA D,HUANG W,SZATMARY P,et al.Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis:Systematic review and meta-analysis[J].Gut,2017,66(8):1354-1355．

[59]ANANTHAKRISHNAN AN,CAGAN A,GAINER VS,et al.Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease[J].J Crohns Colitis,2014,8(9):956-963．

[60]JUNG YS,HAN M,PARK S,et al.Cancer risk in the early stages of inflammatory bowel disease in Korean patients:A nationwide population-based study[J].J Crohns Colitis,2017,11(8):954-962．

[61]CHAMS S,BADRAN R,SAYEGH SE,et al.Inflammatory bowel disease:Looking beyond the tract[J].Int J Immunopathol Pharmacol,2019,33:2058738419866567．

[62]GARRIDO GMEZ E,LOPEZ SAN ROMN A,BERMEJO SANJOSF.Idiopathic pancreatitis in inflammatory bowel disease[J].JCrohns Colitis,2008,2(3):237-240．

[63]MOOLSINTONG P,LOFTUS EV Jr,CHARI ST,et al.Acute pancreatitis in patients with Crohn's disease:Clinical features and outcomes[J].Inflamm Bowel Dis,2005,11(12):1080-1084．

[64]GARCIA GARCIA DE PAREDES A,RODRIGUEZ de SANTIAGO E,RODRIGUEZ-ESCAJA C,et al.Idiopathic acute pancreatitis in patients with inflammatory bowel disease:A multicenter cohort study[J].Pancreatology,2020,20(3):331-337．

[65]BROIDE E,DOTAN I,WEISS B,et al.Idiopathic pancreatitis preceding the diagnosis of inflammatory bowel disease is more frequent in pediatric patients[J].J Pediatr Gastroenterol Nutr,2011,52(6):714-717．

[66]van DIJK SM,HALLENSLEBEN N,van SANTVOORT HC,et al.Acute pancreatitis:Recent advances through randomised trials[J].Gut,2017,66(11):2024-2032．

[67] HEIKIUS B,NIEMELS,LEHTOLA J,et al.Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease[J].Am J Gastroenterol,1999,94(4):1062-1069．

[68]BOKEMEYER B.Asymptomatic elevation of serum lipase and amylase in conjunction with Crohn's disease and ulcerative colitis[J].Z Gastroenterol,2002,40(1):5-10．

[69]TROMM A,HLTMANN B,HPPE D,et al.Hyperamylasemia,hyperlipasemia and acute pancreatitis in chronic inflammatory bowel diseases[J].Leber Magen Darm,1991,21(1):15-16,19-22．

[70]TODA N,AKAHANE M,KIRYU S,et al.Pancreas duct abnormalities in patients with ulcerative colitis:A magnetic resonance pancreatography study[J].Inflamm Bowel Dis,2005,11(10):903-908．

[71]BARTHET M,LESAVRE N,DESPLATS S,et al.Frequency and characteristics of pancreatitis in patients with inflammatory bowel disease[J].Pancreatology,2006,6(5):464-471.

施引文献

资源附件(0)

访问统计